Answers are grounded in this paper and cite their sources.
Staphylococcus aureus IsdI is a heme oxygenase enzyme that degrades heme to staphylobilin products that are distinct from the biliverdin products of human heme oxygenase. IsdI contains an essential second-sphere tryptophan residue, and the relative steric and electronic contributions of this residue to IsdI-catalyzed heme oxygenation were unclear prior to this work. The W66Y and W66F substitutions similarly decrease the rate of IsdI-catalyzed heme degradation, but the reduction potentials of Tyr and Phe are significantly different. Liquid chromatography-mass spectrometry (LC-MS) characterization of the wild-type (WT) IsdI reaction products indicates that a near equal mixture of staphylobilin and formyl-oxo-bilin is present in the crude reaction mixture, plus a smaller amount of biliverdin. Notably, WT IsdI exhibits a significant bias towards δ-staphylobilin production with this isomer representing 87 ± 1% of the staphylobilin reaction products. This is especially surprising considering that WT IsdI yields a near equal mixture of β- and δ-biliverdin minor products. The heme degradation product ratios, and their isomeric distributions, are different for W66Y and W66F IsdI. These data are consistent with a concerted rearrangement mechanism for the first oxygenation reaction catalyzed by IsdI, and the data for W66Y and W66F IsdI suggests that the reactivity of the meso-hydroxyheme intermediate depends upon the solvent accessibility of the active site. Finally, the regioselectivity of the third oxygenation reaction catalyzed by IsdI can be explained by a deformylation mechanism that includes outer-sphere electron transfer from the indole ring of the second-sphere tryptophan to the conjugated π system of the linear tetrapyrrole.
No takes yet. Share an insight, caveat, or question.
Kocian et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: